Premier Sponsor

Carl Zeiss Meditec

Carl Zeiss Meditec, a world-leading medical technology company, supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete solutions for diagnosis and treatment of eye diseases, innovative visualization solutions for microsurgery, and promising, future-oriented technologies such as intraoperative radiotherapy.

Major Sponsor


Allergan (NYSE: AGN) is a unique, global pharmaceutical company focused on developing, manufacturing and commercializing high quality generic and innovative branded pharmaceutical products for patients around the world.  The Company has approximately 30,000 employees worldwide and maintains global headquarters in Dublin, Ireland.

Supporting Sponsors

Bausch + Lomb

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight. Bausch + Lomb is a global hallmark for innovation and quality, offering the widest and finest range of eye health products including ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments.

Johnson & Johnson Vision

Johnson & Johnson Vision is committed to improving and restoring sight for patients worldwide. Through their world-leading ACUVUE® Brand Contact Lenses portfolio, newly acquired cataract surgery, laser refractive surgery (LASIK) and consumer eye health businesses, they now serve more than 60 million patients a day across 103 countries. Dual headquartered in Jacksonville, Florida, and Santa Ana, California, Johnson & Johnson Vision has more than 8,400 employees worldwide.

Innovation Sponsors


Eyenovia, Inc. (NASDAQ: EYEN) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. The Optejet™ piezo-print smart delivery platform is disruptive to the 100 year legacy eyedropper paradigm. The Optejet(tm) dispenser gently and accurately coats the ocular surface with a micro-dose of medication, while also potentially reducing dose-related ocular toxicity and side effects. Recently, we reported that a single microdose of latanoprost, delivering 75% less drug and preservative than a standard eyedrop, achieved 29% IOP lowering from baseline versus the 26% effect seen in other studies of conventional eyedrops. In addition to CACG, Eyenovia’s pipeline is currently focused on late-stage therapies for myopia progression, mydriasis and other eye diseases.

Kala Pharmaceuticals

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ Drug Delivery Technology, with an initial focus on the treatment of eye diseases. Kala’s first approved is INVELTYS, the first and only corticosteroid for the treatment of inflammation and pain following ocular surgery. Kala’s lead pipeline candidate is KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease, for which a New Drug Application (NDA) has been filed with the FDA and a target action date under the Prescription Drug User Fee Act (PDUFA) has been set for August 15, 2019.


MacuLogix, equips eye care professionals with the instrument, tools and education needed to effectively diagnose and treat patients with age-related macular degeneration (AMD). AMD is a chronic, progressive disease that impacts over 170 million people worldwide and goes undiagnosed in at least 25% of patients. The company's AdaptDx automated dark adaptometer measures a patient's ability to adjust from light to darkness. This dark adaptation function is compromised from the earliest stages of disease, indicating the presence of AMD with 90% accuracy at least three years before drusen are visible. To help achieve its vision of eliminating preventable blindness caused by AMD, MacuLogix partners with eye care professionals to provides in-practice training and treatment best practices to support the implementation and optimization of the AdaptDx.


Novaliq is a pharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free eye drop technology. Novaliq offers an industry-leading portfolio addressing the needs of eye disease patients. Lead assets in clinical development are: CyclASol®, an anti-inflammatory and immunomodulating drug for the treatment of dry eye disease with a demonstrated early onset of action and an excellent tolerability; and NOV03, the first drug addressing evaporative DED associated with meibomian gland dysfunction. NovaTears® water-free eye drops for dry eye have CE Marking and are commercialized in Australia/New Zealand by AFT Pharmaceuticals and in Europe as EvoTears® by Ursapharm. Headquartered in Heidelberg/Germany, Novaliq has an office in Cambridge, MA/USA. Long-term shareholder is dievini Hopp BioTech Holding

Ocunexus Therapeutics

Ocunexus is a clinical stage company developing compounds shutting down the inflammasome pathway of inflammation. Physiologically hemichannels are continuously forming in cell membranes and remain closed until docked with a neighboring cell at which point they open to form gap junctions. In multiple disease states the connexin43 (Cx43) hemichannel protein is overexpressed and the hemichannel opens prematurely allowing for ATP to enter the extracellular space. ATP assembles the innate inflammasome (NLRP3) pathway of inflammation resulting in release and continuing cycling of multiple proinflammatory cytokines. Ocunexus lead compound is Xiflam a Phase 2B ready orally administered Cx43 inhibitor in development for Geographic Atrophy and Diabetic Retinopathy.
Ocunexus has also developed a Peptide which is a Cx43 hemichannel inhibitor for intravitreal use in posterior segment disease.

Oyster Point Pharma

Oyster Point is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The company’s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the Trigeminal Parasympathetic Pathway (TPP) to activate the glands responsible for tear film production. Oyster Point Pharma is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate tear film production by delivering therapy as a nasal spray in patients with Dry Eye Disease (DED).

Sight Sciences

In 2011, Sight Sciences was founded to change the way the practice of ophthalmology and optometry thinks about and treats the leading causes of eye disease. Supported by leading medical technology and private equity investors, Sight Sciences operates two business lines: surgical and non-surgical systems. Its surgical product portfolio consists of the OMNI™ Surgical System, TRAB®360 and VISCO360® for use by ophthalmologists. Its non-surgical product portfolio consists of its TearCare™ technologies for use by ophthalmologists and optometrists.


SightGlass Vision

SightGlass Vision, Inc. is a clinical-stage medtech startup company focused on ending myopia.

Media Partners

Bryn Mawr Communications

Bryn Mawr Communications’ (BMC) eye care publications are uniquely positioned in ophthalmology to serve both physicians’ and industry’s needs.

Cataract & Refractive Surgery TodayCataract & Refractive Surgery Today Europe, Glaucoma Today, Retina Today, MillennialEYE, and CollaborativeEYE showcase in-depth coverage of surgical approaches, device development, pharmacologic innovations, industry trends, and practice management.

By partnering with key opinion leaders, BMC’s eye care publications balance institutional wisdom with fresh perspectives through print magazines, an expansive video library, and timely news feeds. BMC’s in-house production team brings information directly to physicians through live meetings, simulcasted symposia, live surgeries, and more.

Optometry Times

Optometry Times delivers easily digested, practical information by ODs for ODs. This information can be immediately applied to improve the clinical experience of the next patient in your chair as well as your practice performance. In partnering with our readers, Optometry Times provides data, analysis, tools, and resources which are available whenever and wherever our readers want them. Visit optometrytimes.com to check out content to help your patients and your practice.

Review of Optometry

With over 129 years serving the profession, Review of Optometry continues the mission by offering clinical reviews, case studies, contact lens information, practice management, and market trend news. Review reaches over 40,000 optometrists monthly and CE programs are available in print and online as part of Review's commitment to the profession.

Supporting Organization


The mission of Ethis, Inc., is to facilitate global innovation in eyecare by providing strategic analysis, exceptional content across a wide range of media, and an extensive network of key ophthalmic and optometric opinion leaders to our industry and academic partners around the world.